Category: Uncategorized

A state-licensed youth psychiatric facility is under fire after a three-year study found repeated abuses, high restraint rates and a string of broken promises to reform.

The Southern Peaks Regional Treatment Center (SPRTC) in Cañon City, Colorado, is a facility specializing in the housing and treatment of youth aged 10–18 who have “significant emotional, social, behavioral and/or psychiatric disorders.”

“Let me out. I didn’t know it was this bad.” —Youth Resident, Southern Peaks Regional Treatment Center

What exactly that “treatment” consists of was laid bare in a report by Disability Law Colorado (DLC), a nonprofit advocacy organization.

“Unsafe” is one of the delicate adjectives used in the report to describe conditions at SPRTC. “Often unkind” is the phrase used to characterize the staff, who, according to various children, will say things to them like, “you suck” and “you’re a piece of crap.”

One child said he was told to “go kill myself.”

Name-calling is one thing, but physical abuse in the form of excessive restraints and coercive “therapy” is another.

“SPRTC continues to be more broadly known for their use of restraints rather than treatment.”

The case of Brandy Fogle’s autistic 13-year-old son appears to be a typical one. Fogle, who has been at the facility since January, is restrained multiple times weekly, for up to one hour and 20 minutes. “I can’t imagine,” Ms. Fogle said, “being held down by four to five adults for a few minutes, let alone an hour and 20 minutes.”

The brutality inflicted on her son is among the roughly 75 documented restraint incidents per month at SPRTC as of May 2025—a rate significantly higher than other comparable facilities in Colorado.

The cruel use of restraints is mirrored in the facility’s unsafe conditions and its striking lack of care and compassion. “We have had numerous children report to us that they have received raw or undercooked food, including raw chicken,” says DLC. “Multiple children have reported getting food poisoning while in the care of SPRTC.”

And as for the housing, it “cannot be described as feeling homelike,” the report discloses. “Children have metal beds and dark rooms with breakable windows. Their common areas are filled with furniture that is often found in correctional settings like jails and prisons. This furniture is even less homelike and welcoming than the furniture in juvenile corrections facilities in Colorado.”

Or as one child expressed, “It’s like jail.”

SPRTC claimed to have set up a Youth Advisory Council to allow for feedback from residents about the facility, but when the DLC visited, there was no such council.

Read more…

Drug regulatory agencies in Germany and Australia have added warnings that atomoxetine can trigger violent or suicidal thoughts—sparking urgent concern over its long‑term use in children and adults.

Why on God’s little green earth would you give your child a drug that experts say can make them homicidal or suicidal?

And why would you ever take such a drug yourself?

The answer is: You wouldn’t. But for well over 20 years, millions of Americans have been taking—and giving their kids—the psychiatric drug atomoxetine.

And now, drug regulatory agencies in both Germany and Australia have issued warnings that the drug can cause homicidal and suicidal behavior and thoughts.

That’s right—the drugs you’re giving your children on the advice of psychiatrists can make them want to kill you.

“The idea that a drug prescribed to millions of children and adults could induce homicidal behavior is nothing short of astonishing.”

Read more here.

Psychiatrist Joanna Moncrieff indicts her entire industry for falsely pushing deadly drugs as a “treatment” for depression. Her conclusion: They don’t work. And she’s got the evidence to prove it. 

This was not on their Bingo card.

The psychiatric community awoke one morning in mid-January to find the foundations of their cash-cow alliance with Big Pharma yanked out from underneath them—and by one of their own.

A new history of antidepressants, authored by a psychiatrist, doesn’t so much make the case for the falsehood of the chemical treatment of depression as it does annihilate it.

Granularly researched with evidence as airtight as it is brutal, Chemically Imbalanced: The Making and Unmaking of the Serotonin Myth by Dr. Joanna Moncrieff, a professor of psychiatry at University College London, indicts and convicts her entire industry for knowingly hawking deadly drugs on the for-profit pretense of “treating” depression.

Dr. Moncrieff resolved to unmask the fraud after leading a team of five top UK and European specialists on a review of studies to determine if there was, in fact, a relationship between the chemical serotonin and depression. Since the 1960s, psychiatrists have insisted—in articles, papers, websites and every platform they could shout from—that a “below-normal” amount of the so-called “feel-good” chemical serotonin is the cause of misery. Then, with the advent of “Selective Serotonin Reuptake Inhibitor” (SSRI) antidepressants in the 1990s, “chemical imbalance” became the Golden Calf psychiatrists and pharmaceutical giants worshipped: Simply jack up the depressed person’s serotonin with antidepressant snake-oil drugs that enrich psychiatrists and Big Pharma and thus remedy that “chemical imbalance.”

But Dr. Moncrieff and her team have thrown cold water on the “you’re-depressed-because-you-need-your-chemicals-rebalanced” party. In findings published in the journal Molecular Psychiatry, she concluded that “there is no evidence of a connection between reduced serotonin levels of activity and depression.”

Read the rest of this article here.

By CCHR National

The U.S. drug regulatory agency examined evidence presented by the company requesting approval for MDMA (ecstasy) and reports from experts examining that evidence before denying approval for the drug as mental health treatment. A medical journal has just retracted three MDMA therapy research papers for ethical violations.

Washington, DC – August 13, 2024 — The U.S. Food and Drug Administration (FDA) has rejected the psychedelic drug MDMA, commonly known as ecstasy or molly, as treatment for post-traumatic stress, a decision that Citizens Commission on Human Rights (CCHR) advocated in its statement submitted to the FDA during a public comment period earlier this year. The FDA’s decision ends the first attempt to gain the agency’s approval for a psychedelic drug treatment.

The FDA concurred with the findings of its advisory committee of independent experts, which held a public hearing in June on the use of MDMA for psychedelic-assisted psychotherapy. The committee voted overwhelmingly that the company which applied for drug approval, Lykos Therapeutics, failed in its clinical trials to prove the treatment was effective, and that benefits from the drug therapy did not outweigh the risks.  READ MORE